The rise in share price is very welcome. I bought enough under 0.010 to cover previous buys up to 0.240 (remember then?) and am near break even. This took a while to do as at these lows there was only a few thousand dollars being traded in any month. I think the .004 was an intra-day low for a few hundred dollars. Still, a pleasing turn-around.
This company has gone as close to insolvency as I’d like to get, and beggars’ can’t be choosers.
But think of the areas this product impacts on: contact lenses, catheters, legionnaires, cystic fibrosis, oil and gas, dental treatments, etc. What remains to be done to develop this and what’s the upside?
Are D'Sylva, Empire Investments and the new directors saints or sinners? BOS has been taken over, for $120k, and is now being sold. The question must be; are we getting the best value?
The acquisition I see as a side-issue, even a distraction, at the moment.
By the way, I too was wondering where the US$2.6 million came from?
BOS Price at posting:
2.4¢ Sentiment: Hold Disclosure: Held